New Privacy Policy and Terms of Use
Per an email sent to iBridge Network members today…
We’re writing to let you know that our privacy policy and terms of use have been updated. We do not expect to send you many emails of this nature, but sometimes it is necessary.
In addition to this news, we also have some other exciting updates and developments. The iBridge Network now has over 3,000 innovations and research objects posted from 38 campuses located across the United States. With visitors from over 5,200 cities, representing over 150 countries, the Network is moving forward boundlessly.
Innovations listed on the site are in a range of subject areas that vary from cell lines to software to nanotechnology to agricultural substances.
What are you interested in? Perhaps…
- Needle-Free Liquid Jet Injector for Drug and Vaccine Delivery - Most vaccines and protein therapeutics are currently delivered using needles and syringes. Despite their common use, needle-based methods have several limitations such as needle phobia, accidental needle sticks and re-use of needles and syringes in developing countries leading to a large number of HIV and HBV cases.
- Hydrogen Generation from Solar Energy - The idea of splitting water with sunlight is quite old, but the current efficiency of such systems is only 7%-12%. This invention incorporates photovoltaic cells (PV) and micro-chemical reactors to create an integrated device that utilizes light energy to convert water into hydrogen at a more efficient rate than current technologies. The device is compact, scalable, and can be manufactured using conventional integrated circuit manufacturing technology.
- Improved contrast agent for MRI using fluorinated nanoparticles - Washington University is actively seeking partners to further develop an innovative new contrast agent for magnetic resonance imaging that could revolutionize diagnostic imaging. The agent, which uses fluorinated nanoparticles, enhances the use of MRI for diagnosing cardiovascular disease.
- Test Offers Early Detection of Melanomas and Other Cancers - A new blood and tissue test can detect metastatic cancer at an early and treatable stage. This noninvasive test detects over 95% of advanced melanomas and is up to 1,000-fold more sensitive than other testing methods, enabling it to detect very low levels of cancer.
Keep visiting the iBridge Web site or subscribe to find out about the new innovations posted to the site regularly.
Who knows what you’ll find?
Best,
P.S. Watch for the upcoming inaugural issue of the iBridge Network Newsletter. In this regular publication, you will enjoy learning more about what the Network is doing as well as the work of the Kauffman Foundation in the area of advancing innovation and entrepreneurism.